Advertisement
Screener

PASITHEA THERAPEUTICS CORP. (KTTA) Pre-Tax Income

2.8 / 5 stars · 68/120 Roast Me

PASITHEA THERAPEUTICS CORP. Pre-Tax Income

PASITHEA THERAPEUTICS CORP. (KTTA) reported Pre-Tax Income of -$5.27 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.

Financial Statements › Income Statement

us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest · last filed 2026-08-14

  • PASITHEA THERAPEUTICS CORP. income (loss) from continuing operations before income taxes, noncontrolling interest for the quarter ending 2026-06-30 was -$5.27M.
  • PASITHEA THERAPEUTICS CORP. income (loss) from continuing operations before income taxes, noncontrolling interest for the quarter ending 2026-03-31 was -$2.87M.
  • PASITHEA THERAPEUTICS CORP. income (loss) from continuing operations before income taxes, noncontrolling interest for the quarter ending 2025-12-31 was -$10.11M.
  • PASITHEA THERAPEUTICS CORP. income (loss) from continuing operations before income taxes, noncontrolling interest for the quarter ending 2025-09-30 was -$3.04M.
  • PASITHEA THERAPEUTICS CORP. income (loss) from continuing operations before income taxes, noncontrolling interest for fiscal 2025 was -$20.43M.
  • PASITHEA THERAPEUTICS CORP. income (loss) from continuing operations before income taxes, noncontrolling interest for fiscal 2024 was -$13.90M.
  • PASITHEA THERAPEUTICS CORP. income (loss) from continuing operations before income taxes, noncontrolling interest for fiscal 2023 was -$15.51M.
  • PASITHEA THERAPEUTICS CORP. income (loss) from continuing operations before income taxes, noncontrolling interest for fiscal 2022 was -$11.73M.
Period endIncome (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest 3 monthIncome (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest 3 month as first filedIncome (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest 5 monthIncome (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest 6 monthIncome (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest 6 month as first filedIncome (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest 8 monthIncome (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest 9 monthIncome (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest 9 month as first filedIncome (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest 12 monthIncome (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest 12 month as first filed
2026-06-30-$5.27M
10-Q · filed 2026-08-14
-$8.14M
10-Q · filed 2026-08-14
-$18.25M
derived: sum of 3 quarters · filed 2026-08-14
-$21.29M
derived: sum of 4 quarters · filed 2026-08-14
2026-03-31-$2.87M
10-Q · filed 2026-05-15
-$12.98M
derived: sum of 2 quarters · filed 2026-05-15
-$16.02M
derived: sum of 3 quarters · filed 2026-05-15
-$19.73M
derived: sum of 4 quarters · filed 2026-08-14
2025-12-31-$10.11M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30
-$13.15M
derived: sum of 2 quarters · filed 2026-03-30
-$16.86M
derived: sum of 3 quarters · filed 2026-08-14
-$20.43M
10-K · filed 2026-03-30
2025-09-30-$3.04M
10-Q · filed 2025-11-13
-$6.75M
derived: sum of 2 quarters · filed 2026-08-14
-$10.32M
10-Q · filed 2025-11-13
-$13.49M
derived: sum of 4 quarters · filed 2026-08-14
2025-06-30-$3.72M
10-Q · filed 2026-08-14
-$7.28M
10-Q · filed 2026-08-14
-$10.46M
derived: sum of 3 quarters · filed 2026-08-14
-$13.46M
derived: sum of 4 quarters · filed 2026-08-14
2025-03-31-$3.56M
10-Q · filed 2026-05-15
-$6.74M
derived: sum of 2 quarters · filed 2026-05-15
-$9.74M
derived: sum of 3 quarters · filed 2026-05-15
-$13.61M
derived: sum of 4 quarters · filed 2026-05-15
2024-12-31-$3.18M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30
-$6.18M
derived: sum of 2 quarters · filed 2026-03-30
-$10.04M
derived: sum of 3 quarters · filed 2026-03-30
-$13.90M
10-K · filed 2026-03-30
2024-09-30-$3.00M
10-Q · filed 2025-11-13
-$6.87M
derived: sum of 2 quarters · filed 2025-11-13
-$10.73M
10-Q · filed 2025-11-13
-$15.76M
derived: sum of 4 quarters · filed 2025-11-13
2024-06-30-$3.87M
10-Q · filed 2025-08-14
-$7.73M
10-Q · filed 2025-08-14
-$12.76M
derived: sum of 3 quarters · filed 2025-08-14
-$16.37M
derived: sum of 4 quarters · filed 2025-08-14
2024-03-31-$3.86M
10-Q · filed 2025-05-15
-$8.89M
derived: sum of 2 quarters · filed 2025-05-15
-$12.50M
derived: sum of 3 quarters · filed 2025-05-15
-$16.10M
derived: sum of 4 quarters · filed 2025-05-15
2023-12-31-$5.03M
derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-24
-$8.64M
derived: sum of 2 quarters · filed 2025-03-24
-$12.24M
derived: sum of 3 quarters · filed 2025-03-24
-$15.51M
10-K · filed 2025-03-24
2023-09-30-$3.61M
10-Q · filed 2024-11-13
-$7.21M
derived: sum of 2 quarters · filed 2024-11-13
-$10.48M
10-Q · filed 2024-11-13
-$14.53M
derived: sum of 4 quarters · filed 2024-11-13
2023-06-30-$3.60M
10-Q · filed 2024-08-13
-$6.86M
10-Q · filed 2024-08-13
-$10.92M
derived: sum of 3 quarters · filed 2024-08-13
-$15.11M
derived: sum of 4 quarters · filed 2024-08-13
2023-03-31-$3.27M
10-Q · filed 2024-05-14
-$7.32M
derived: sum of 2 quarters · filed 2024-05-14
-$11.51M
derived: sum of 3 quarters · filed 2024-05-14
-$13.70M
derived: sum of 4 quarters · filed 2024-05-14
2022-12-31-$4.05M
derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-29
-$8.24M
derived: sum of 2 quarters · filed 2024-03-29
-$10.43M
derived: sum of 3 quarters · filed 2024-03-29
-$11.73M
10-K · filed 2024-03-29
-$13.94M
10-K · filed 2023-03-30
2022-09-30-$4.19M
10-Q · filed 2023-11-13
-$4.59M
10-Q · filed 2022-11-14
-$6.38M
derived: sum of 2 quarters · filed 2023-11-13
-$7.67M
10-Q · filed 2023-11-13
-$8.82M
10-Q · filed 2022-11-14
-$7.04M
derived: sum of 4 quarters · filed 2023-11-13
2022-06-30-$2.19M
10-Q · filed 2023-08-11
-$2.66M
10-Q · filed 2022-08-15
-$3.48M
10-Q · filed 2023-08-11
-$4.23M
10-Q · filed 2022-08-15
-$2.85M
derived: sum of 3 quarters · filed 2023-08-11
-$4.38M
derived: sum of 4 quarters · filed 2023-08-11
2022-03-31-$1.29M
10-Q · filed 2023-05-12
-$1.57M
10-Q · filed 2022-05-16
-$663.44K
derived: sum of 2 quarters · filed 2023-05-12
-$2.19M
derived: sum of 3 quarters · filed 2023-05-12
-$2.92M
derived: sum of 4 quarters · filed 2023-05-12
2021-12-31$630.14K
derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-30
-$895.97K
derived: sum of 2 quarters · filed 2023-03-30
-$1.62M
derived: sum of 3 quarters · filed 2023-03-30
-$2.17M
10-K · filed 2023-03-30
2021-09-30-$1.53M
10-Q · filed 2022-11-14
-$2.25M
derived: sum of 2 quarters · filed 2022-11-14
-$2.80M
10-Q · filed 2022-11-14
2021-06-30-$727.95K
10-Q · filed 2022-08-15
-$1.28M
10-Q · filed 2022-08-15
2021-03-31-$549.61K
10-Q · filed 2022-05-16
2020-12-31-$40.98K
10-K · filed 2022-03-30
2020-09-30-$13.97K
10-Q · filed 2021-11-18
-$13.97K
10-Q · filed 2021-11-18

Similar stocks

Stock NameCountryMarket CapPE Ratio
Allarity Therapeutics, Inc. (ALLR)United States$0.017B-1.66
PALATIN TECHNOLOGIES INC (PTN)United States$0.017B-5.36
Lipocine Inc. (LPCN)United States$0.017B-1.79
Biofrontera Inc. (BFRI)United States$0.018B-2.13
Korsana Biosciences, Inc. (CYCN)United States$0.016B
Citius Pharmaceuticals, Inc. (CTXR)United States$0.016B-133.06
Lantern Pharma Inc. (LTRN)United States$0.015B-2.87
Anebulo Pharmaceuticals, Inc. (ANEB)United States$0.015B
ACTUATE THERAPEUTICS, INC. (ACTU)United States$0.015B
Rocket One Inc. (RKTO)United States$0.019B